FDA Grants Orphan Drug Designation For Lennox-Gastaut Syndrome Treatment
Source: Pixabay

FDA Grants Orphan Drug Designation For Lennox-Gastaut Syndrome Treatment

Lennox-Gastaut syndrome (LGS) is a severe and rare form of epilepsy, which causes patients to often have multiple seizures a day. It generally appears in early childhood, and is difficult to treat. In severe cases, it may be fatal. To learn more about LGS, click here.

Ovid Therapeutics Inc., a company that focuses on creating medicines for people with rare diseases, saw the need for a better LGS treatment. They have been working with Takeda Pharmaceutical Company Limited on the treatment TAK-935/OV935.

On January 20th, the company announced that TAK-935/OV935 had received Orphan Drug Designation from the FDA to speed up the process.
Learn more about it on Public here.